GlaxoSmithKline (LON:GSK) Receives “Buy” Rating from UBS Group

GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating reiterated by research analysts at UBS Group in a research report issued to clients and investors on Thursday, September 27th, investing.thisismoney.co.uk reports. They presently have a GBX 1,700 ($22.21) target price on the stock. UBS Group’s price target indicates a potential upside of 18.93% from the company’s previous close.

A number of other analysts also recently issued reports on GSK. Citigroup reiterated a “neutral” rating on shares of GlaxoSmithKline in a report on Thursday, July 26th. Berenberg Bank reissued a “buy” rating and issued a GBX 1,790 ($23.39) price objective (down from GBX 1,790 ($23.39)) on shares of GlaxoSmithKline in a research note on Wednesday, August 1st. Goldman Sachs Group set a GBX 1,900 ($24.83) price objective on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research note on Friday, June 29th. Barclays set a GBX 1,750 ($22.87) price objective on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research note on Tuesday, July 3rd. Finally, JPMorgan Chase & Co. set a GBX 1,550 ($20.25) price objective on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Tuesday, July 10th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and ten have issued a buy rating to the stock. GlaxoSmithKline has an average rating of “Hold” and an average price target of GBX 1,533.55 ($20.04).

LON GSK traded down GBX 22.20 ($0.29) on Thursday, reaching GBX 1,429.40 ($18.68). The company had a trading volume of 12,405,381 shares, compared to its average volume of 9,120,000. GlaxoSmithKline has a 12 month low of GBX 1,235.20 ($16.14) and a 12 month high of GBX 1,724.50 ($22.53).

In related news, insider Philip R. Hampton acquired 2,810 shares of the stock in a transaction on Wednesday, July 25th. The stock was bought at an average cost of GBX 1,557 ($20.34) per share, with a total value of £43,751.70 ($57,169.35). Also, insider David Redfern sold 1,925 shares of the business’s stock in a transaction dated Tuesday, July 31st. The shares were sold at an average price of GBX 1,575 ($20.58), for a total transaction of £30,318.75 ($39,616.82). Over the last three months, insiders acquired 2,835 shares of company stock valued at $4,413,165.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: Investing strategies using the yield curve

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply